Navigation Links
Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
Date:3/2/2009

Highly Statistically Significant Results Achieved at Two Dose Levels with No Reversal of Analgesia

SAN CARLOS, Calif., March 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced positive topline results today from a Phase 2 double-blind, randomized, placebo-controlled study of NKTR-118 in patients with opioid-induced constipation (OIC). NKTR-118, a peripheral opioid antagonist, is an oral once-a-day investigational drug to treat OIC, the most common and debilitating manifestation of opioid-bowel dysfunction (OBD). The Phase 2 study of NKTR-118 is terminating early on the basis of overwhelming evidence of efficacy at two different dose levels of 25 mg once daily and 50 mg once daily. The study achieved a clinically meaningful and highly statistically significant, dose-dependent increase in spontaneous bowel movements (SBMs) from baseline after the first week of NKTR-118 treatment with the 25 mg dose and the 50 mg dose versus placebo (p < 0.01 for all comparisons). Patients receiving the 25 mg dose of NKTR-118 had an average of 5.1 SBMs during the first week of treatment as compared to 1.5 SBMs per week during the baseline period. Patients receiving the 50 mg dose of NKTR-118 had an average of 5.7 SBMs during the first week of treatment versus 1.6 SBMs per week during the baseline period. The increase in SBMs versus placebo was maintained over the 28-day treatment period (p <0.01). More importantly, in the 25 mg and 50 mg dose cohorts, there was no reversal of analgesia as measured by a change in pain Numerical Rating Scale (NRS) and no increase in opiate use.

"These data show that NKTR-118 taken orally once-daily at the 25 mg and 50 mg dose levels dramatically increased bowel movements within the first week of treatment for patients with OIC," said Lynn R. Webster, M.D., Medical Director, Lifetre
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
2. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
3. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
4. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
5. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
8. TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee
9. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
10. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  MedScope ( www.medscope.org ), the leading provider of ... Connected World magazine Connected World Award for ... can be used anywhere, anytime. The nomination was made ... In nominating MedScope, Landon Garner , Director of ...
(Date:1/23/2015)... 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is ... Advaxis, Inc. ("Advaxis" or the "Company") (NASDAQ: ... fiduciary duties to shareholders. On January 21, ... reporting that Advaxis had misrepresented the clinical data for ...
(Date:1/23/2015)... 23, 2015  Now available for sale, The Armor1 Ankle ... prevents ankle sprains by cushioning the ankle from an ... around the outside of any shoe type and allows ... still offering protection against sprains. With customers in physical ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2
... Reportlinker.com announces that a new market research report is ... Pharmaceutical Packaging Market http://www.reportlinker.com/p0288103/US-Pharmaceutical-Packaging-Market.html ... 5.5% annually through 2014 Demand for ... increase 5.5 percent annually to $18.4 billion in 2014. ...
... Inc. (PSI), a leading pharmaceutical Contract Research Organization ... to help advance early stage molecules and drug ... Under the established framework between Children,s and PSI, ... at progressing the specific drug or drug product ...
Cached Medicine Technology:Reportlinker Adds US Pharmaceutical Packaging Market 2Reportlinker Adds US Pharmaceutical Packaging Market 3Reportlinker Adds US Pharmaceutical Packaging Market 4Reportlinker Adds US Pharmaceutical Packaging Market 5Reportlinker Adds US Pharmaceutical Packaging Market 6Reportlinker Adds US Pharmaceutical Packaging Market 7Reportlinker Adds US Pharmaceutical Packaging Market 8Reportlinker Adds US Pharmaceutical Packaging Market 9Reportlinker Adds US Pharmaceutical Packaging Market 10Children's Hospital Boston and Particle Sciences Cooperate on Translational Medicine Efforts 2
(Date:1/22/2015)... PA (PRWEB) January 22, 2015 Woodloch Pines, ... Mountains, has been selected by TripAdvisor as the number one ... the 6th best in the world for their annual Travelers’ ... online travel community . The website is home to millions ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put ... muscle by up to 30lbs in less than 12 weeks ... Stan Stevenson, prompting an investigative review. , “Our Incredible ... diet formula that allows the body to pack on a ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... has released a new blog post explaining the main features ... , Auto insurance quotes help many drivers find the best ... call an agent or visit an agency for price information. ... http://autocarinsurancebest.com/ . , Every business who relies heavily on ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... a tattoo done of their lover's initials due to fear ... news - researchers have discovered a technique, where the cryptic ... wearer's choice. ,The new method is called micro-encapsulation, ... microcapsules, that are as tiny as pins, can bear a ...
... skin cancer many people still disregard the use of sunscreen to ... that one in three Briton do not protect their skin ... skin cancer are diagnosed in the UK each year, and recent ... in the next 30 years. ,Research by the ...
... on controlling immune system responses, announced the acquisition ... in organ transplantation. ,Circassia acquired the ... of Birmingham in the UK for an undisclosed ... on product sales. Scientifically, the ToleroTrans approach mirrors ...
... Hundreds of cyclists will be participating in the Memory Ride ... raising money to fight the disease that affects more ... in the 11th annual Memory Ride has a personal story ... family friend who has struggled with the disease. ...
... revolution this weekend when a fleet of 10,000 self-service bicycles hits ... metro for Parisians and tourists alike. ,As the Tour ... country, in Paris amateur cyclists will from Sunday be able to ... for short trips, dropping them off at any of 750 bike ...
... While the overall cost-effectiveness of Medicare benefits have been ... uninsured before receiving benefits at age 65 required ... been privately insured prior to receiving Medicare. These findings, ... the July 12 issue of the New England Journal ...
Cached Medicine News:Health News:Sun Protection Ignored Despite Warnings 2Health News:Paris Set for Pedal Power Revolution 2Health News:Paris Set for Pedal Power Revolution 3Health News:Uninsured Adults Increase Medicare Costs 2Health News:Uninsured Adults Increase Medicare Costs 3
...
...
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 35G x 5/8in (.50 x 16mm)...
Medicine Products: